 Azlactone activated polyalkylene oxides conjugated to biologically active nucleophiles |
| OF THE PREFERRED EMBODIMENT The azlactone activated polyalkylene oxides of the present invention ... |
|
| Biologically compatible linear block copolymers of polyalkylene oxide and peptide units |
| INCLUSIVE OF PREFERRED EMBODIMENTS We have discovered that linear block copolymers comprising ... |
|
| Polyoxypropylene/polyoxyethylene copolmers with improved biological activity |
| Although the prior art preparations of polyoxypropylene/polyoxyethylene block copolymers may have ... |
|
| Nucleic acid probes immobilized on polystyrene surfaces |
| We claim: 1. An article of manufacture for use in a solution phase nucleic acid sandwich ... |
|
| High molecular weight polymer-based prodrugs |
| The present invention addresses the shortcomings described above. In one aspect of the invention, ... |
|
| Non-antigenic branched polymer conjugates |
| OF THE INVENTION 1. POLYMER SUBSTITUENTS AND FORMULA (I) DEFINED The activated branched polymers ... |
|
|
Oligonucleotide derivatives and production thereof
| Details |
Inventors: Miyoshi, Kenichi; Fuwa, Toru;
Assignee: Wakunaga Seiyaku Kabushiki Kaisha (Osaka, JP)
Primary Examiner: Brown; Johnnie R.
Assistant Examiner: Tou; Jenny
Attorney, Agent or Firm: Oblon, Fisher, Spivak, McClelland & Maier
An oligonucleotide derivative having an amino group protected with an eliminatable group bonded through a phosphate group and a spacer with an appropriate length to the 5'-end of an oligonucleotide protected suitably at the 3'-hydroxyl group and the base moiety of the nucleotide, and an immobilized oligonucleotide derivative having a Sepharose carrier bonded to the amino group in place of said protective group are disclosed. Methods for production of these derivatives are also disclosed. |
|
DETAILED DESCRIPTION Gist In view of the state of the art as described above, the present inventors have developed an immobilized oligonucleotide which is useful in purification of nucleic acids and is utilizable for affinity resins, and a method of producing the same.
The present inventors have previously developed a method of synthesizing a completely protected oligonucleotide according to the solid-phase synthetic method.
The present inventors have found a method for immobilization, which comprises introducing a functional group capable of being bound with another carrier into the 5'-hydroxyl group of the objective compound synthesized by the solid-phase synthetic method, so as to be bound at said functional group to the carrier.
According to this method, the present inventors have succeeded in synthesizing effectively an immobilized oligonucleotide, in which an oligonucleotide having any desired base sequence is bound at a specific position to a carrier.
The present invention concerns immobilized oligonucleotide derivatives, which can be used also as affinity resins as well as a plural number of oligonucleotide derivatives which can be used as intermediates thereof, and a method for production thereof.
More specifically, the oligonucleotide derivatives according to the present invention can be represented by the following formulae (2), (4) and (5).
The method of producing the oligonucleotide derivatives represented by the following formulae (2), (4) and (5), as expressed conceptionally and comprehensively, comprises causing a compound (1) to react with a compound (0) to produce a compound (2), while, on the other hand, condensing a compound (3') obtained by the nucleic acid synthetic method with a compound (2') which is a derivative of the compound (2) from which the protective group R.
sup.
3 of the 3'-phosphate has been eliminated to produce a compound (4), and removing all the protective groups from this compound to produce a compound (5).
HO(N'.
sub.
p.
sbsb.
x).
sub.
m --R.
sup.
3 ( 0) R
|
| Related patents |
|
|
Process for synthesizing macrocyclic chelates
The invention is a process for synthesizing a 12 membered ring tetraaza macromolecule. The process involves condensing an amide of ethylene diamine having a general ...
|
|
|
Immunoconjugates joined by thioether bonds having reduced toxicity and improved selectivity
I claim: 1. A method for producing a 1:1 protein:anitbody tioether-linked immunoconjugate as a predominant species, comprising the steps of: combining a protein selected ...
|
|
|
Compositions for photodynamic therapy
I claim: 1. A pharmaceutical composition useful for photodynamic therapy which composition contains, as active ingredient, a conjugate of a porphyrin-type ...
|
|
|
Amplifier molecules for enhancement of diagnosis and therapy
As used herein, an "amplifier" or "amplifier molecule" is a chemical compound having a multiplicity of terminal amine moieties, each serving as a locus to which one or ...
|
|
|
Peptide-containing polyethylene glycol derivatives and application thereof
OF THE PREFERRED EMBODIMENTS The present invention will hereinafter be explained in more detail. The peptide-containing polyethylene glycol derivatives of the present ...
|
|
|
Modified HIL-6
OF THE INVENTION Described below is the chemical modification with PEG of at least one amino group of polypeptides possessing IL-6 activities. This modification results ...
|
|
|
Construction of geometrical objects from polynucleotides
By means of the present invention, DNA, RNA and similar polymers may be produced by synthesizing a double stranded segment, preferably with a loop at one end, cleaving ...
|
|
|
Starburst conjugates
In its broadest aspect, the present invention is directed to polymer conjugate materials comprising dense star polymers or starburst polymers associated with desired ...
|
|
|
Intermediates for providing functional groups on the 5' end of oligonucleotides
We claim: 1. A partially protected alcohol of the formula: ##STR10## wherein Y.sup.1 is selected from dimethoxytrityl, monomethoxytrityl, trityl or pixyl, Y.sup.2 is ...
|
|
|
Antiviral polynucleotide conjugates
OF THE INVENTION The present invention provides polynucleotide conjugates characterized by the properties of ligand binding and enhanced stability. In the present ...
|
|
|
Gene Therapy 
